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Abstract
Type 1 diabetes (T1D) results from the autoimmune destruction of insulin-producing beta-cells in the pancreas. Recruitment
of inflammatory cells is prerequisite to beta-cell-injury. The junctional adhesion molecule (JAM) family proteins JAM-B and
JAM–C are involved in polarized leukocyte transendothelial migration and are expressed by vascular endothelial cells of
peripheral tissue and high endothelial venules in lympoid organs. Blocking of JAM-C efficiently attenuated cerulean-induced
pancreatitis, rheumatoid arthritis or inflammation induced by ischemia and reperfusion in mice. In order to investigate the
influence of JAM-C on trafficking and transmigration of antigen-specific, autoaggressive T-cells, we used transgenic mice
that express a protein of the lymphocytic choriomeningitis virus (LCMV) as a target autoantigen in the b-cells of the islets of
Langerhans under the rat insulin promoter (RIP). Such RIP-LCMV mice turn diabetic after infection with LCMV. We found that
upon LCMV-infection JAM-C protein was upregulated around the islets in RIP-LCMV mice. JAM-C expression correlated with
islet infiltration and functional beta-cell impairment. Blockade with a neutralizing anti-JAM-C antibody reduced the T1D
incidence. However, JAM-C overexpression on endothelial cells did not accelerate diabetes in the RIP-LCMV model. In
summary, our data suggest that JAM-C might be involved in the final steps of trafficking and transmigration of antigen-
specific autoaggressive T-cells to the islets of Langerhans.
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Introduction
The pathogenesis of T1D is characterized by the destruction of
insulin producing b-cells by autoaggressive lymphocytes invading
the islets of Langerhans. This inflammatory processes can be
driven by infection with a pancreas-tropic virus or toxin-induced
b-cell necrosis, resulting in the attraction of autoaggressive T cells
to the islets of Langerhans. Local expression of chemokines and
subsequently the upregulation of a variety of adhesion molecules
by endothelial cells facilitate the attraction and transmigration of
leukocytes from the circulation to the islets. We have demonstrated
in the past that blockade of critical chemokines, such as CXCL10
(IP-10, IFNc-inducible protein of 10 kDa), results in the abroga-
tion of T1D in the RIP-LCMV model [1] indicating that cellular
attraction to the islet of Langerhans is a critical step required for
the subsequent destruction of insulin-producing b-cells.
Besides chemokine-mediated attraction of leukocytes to the site
of inflammation, extravasation from the blood vessels through the
endothelial cell layer is required for penetration into the islets.
Within the leukocyte-extravasation cascade, selectins initiate
leukocyte tethering and rolling and the interaction between
integrins and immunoglobulins is required for firm adhesion and
transmigration [2,3]. Selectin-induced rolling allows for a close
proximity to endothelial cells and binding of chemokines (such as
CXCL10) that are displayed on inflamed endothelium. Sub-
sequently, leukocytes are activated via their chemokine receptors
and an array of integrins is expressed at the leukocyte surface.
Interactions between b2-integrin and intracellular adhesion
molecule-1 (ICAM-1) as well as very late antigen-4 (VLA-4) and
vascular cell adhesion molecule-1 (VCAM-1) are crucial for firm
adhesion of leukocytes to the inflamed endothelium [2,3]. Finally,
interaction between JAM-C, which is predominantly expressed on
endothelial cells and the b2-integrin CD11b present on leukocytes,
including diabetogenic T cells in T1D, is required for the
transmigration from the lumen through the endothelial cell layer
into the inflamed tissue [2,3]. ICAM-1 seems to be a key adhesion
molecule during the T1D pathogenesis, since ICAM-1-deficient
NOD mice are protected from T1D and cellular islet infiltration
was strongly reduced when compared to age-matched regular
NOD mice [4]. In the RIP-LCMV model for T1D ICAM-1 is
upreguated around the islets of Langerhans upon LCMV-infection
[5]. In addition, blockade of ICAM-1 resulted in a reduced
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that express hen-egg white lysozyme (HEL) in the b-cells [6].
Interestingly, blockade platelet endothelial cell adhesion molecule-
1 (PECAM-1) had no effect on T cell infiltration although it was
strongly expressed on islet vessels [6]. Mice lacking ICAM-1 are
partially protected from cerulein-induced pancreatitis [7], but the
administration of anti-ICAM-1 antibodies had only little effect [8].
In contrast to ICAM-1, blockade of JAM-C with a neutralizing
antibody reduced the severity of cerulein-induced pancreatitis and
overexpression of JAM-C on endothelial cells enhanced the
cellular infiltration and the acinar cell necrosis [9]. In contrast to
T1D, severe pancreatitis predominantly affects the exocrine part
of the pancreas resulting in the necrosis of acinar cells [8,9]. Thus,
we intended to further investigate if JAM-C is also important in
pathogenesis of T1D in the virus-induced RIP-LCMV model. The
RIP-LCMV model uses either the nucleoprotein (NP) or the
glycoprotein (GP) of LCMV as target antigens expressed by the b-
cells. T1D is induced at a defined time by infection with LCMV
[10]. Thus, the RIP-LCMV allows for a precise characterization
of the inflammation kinetics occurring in the islets of Langerhans
after induction of the autodestructive processes [11]. In the present
work, we analyzed the expression of JAM-C after LCMV-infection
and applied an anti-JAM-C therapy for T1D using neutralizing
antibodies. Further, we assessed if overexpression of JAM-C in
endothelial cells accelerates T1D pathogenesis.
Materials and Methods
Mice and Virus
Generation and screening by PCR of H-2
b RIP-LCMV-GP and
H-2
b RIP-LCMV-NP transgenic mice were as previously de-
scribed [10,12]. pHHNS-JAM-C transgenic mice have been
generated as describe elsewhere [13] and have been backcrossed
to the C57BL/6 background for more than ten generations.
pHHNS-JAM-C mice have been crossed to RIP-LCMV-GP and
RIP-LCMV-NP mice and genotyped by PCR as previously
described for JAM-C [13] and LCMV-GP and –NP [10,12].
LCMV Armstrong clone 53 b (LCMV-Arm) were plaque-purified
three times on Vero cells and stocks were prepared by a single
passage on BHK-21 cells [12]. For induction of T1D in RIP-
LCMV-GP, RIP-LCMV-NP, as well as the double transgenic
RIP-LCMV lines crossed to pHHNS-JAM-C mice 10
4 plaque
forming units (pfu) LCMV-Arm were injected intraperitoneally.
All animal experiments have been approved by the local Ethics
Animal Review Board, Darmstadt, Germany (Reference number:
V54-19c20/15-F143/30).
Blood Glucose Values
Blood samples were obtained from the tail vein. Blood glucose
was monitored with a OneTouch Ultra at weekly intervals.
Animals with blood glucose values over 300 mg/dl were
considered diabetic [5].
Anti-JAM-C Antibody
Rat-anti mouse JAM-C monoclonal antibody clone H33 ([14]
was purified from rat hybridoma cells grown in DMEM, 1%
Ultroser HY and 0.1% FBS. Briefly, the collected hybridoma
supernatants were filtered, precipitated with 45% of ammonium
sulphate, resuspended in PBS and dialysed against PBS. Then the
anti-JAM-C antibodies were purified over Protein G sepharose 4
fast flow over night at 4uC on an end-over-end rotation.
Thereafter the sepharose beads were washed with PBS, the
antibodies were eluted with 0.1 M Triethanolamine (pH 10.5) and
immediately neutralized with 2 M Tris pH 7.5. For in vivo
blockade experiments a rat IgG2a antibody to human CD44
(9B5) [9] was used a isotype-matched control antibody.
Immunohistochemistry
Tissues were immersed in Tissue-Tek OCT (Bayer), and quick-
frozen on dry ice. Using cryomicrotome and sialin-coated
Superfrost Plus slides (Fisher Scientific), 6 mm tissue sections were
cut. Sections were then fixed with 90% ethanol at 220uC, and,
after washing in PBS, an avidin/biotin-blocking step was included
(Vector Laboratories). Primary and biotinylated secondary anti-
bodies (Vector Laboratories) were reacted with the sections for
60 min each, and color reaction was obtained by sequential
incubation with avidin-peroxidase conjugate (Vector Laboratories)
and diaminobenzidine-hydrogen peroxide. Primary antibodies
used were: rat anti-mouse CD8a, rat anti-mouse CD4, rat anti-
mouse CD31 (all from BD Biosciences, Heidelberg, Germany) and
a polyclonal rabbit anti-JAM-C antibody described elsewhere [9].
Immunofluorescence Staining
Pancreas tissue sections of 6 mm were fixed in 90% ethanol at
220uC, washed in PBS and blocked in PBS containing 10% FBS
for 30 min. Primary antibodies rat anti-mouse CD8a (5 mg/ml),
rat anti-mouse CD31 (2.5 mg/ml) (both from BD Biosciences,
Heidelberg, Germany) and a polyclonal rabbit anti-JAM-C
antibody (5 mg/ml) described elsewhere [9] were incubated for
2 h at room temperature in a humified chamber. An Alexa 488-
conjugated goat anti-rabbit IgG (5 mg/ml) and a Texas Red-
conjugated goat anti-rat IgG (2.5 mg/ml) were used as secondary
antibody. Section were counterstained with 4,6-diamidino-2-
phenylindiole (DAPI) (200 ng/ml) (Sigma-Aldridge, Munich,
Germany). Fluorescence images were acquired with an Axiovert
135 TV fluorescence microscope (Zeiss, Jena, Germany). Fluores-
cence intensities were determined using the Quantity One
software (Bio Rad, Munich, Germany).
Flow Cytometry
For intracellular stains, single-cell suspensions of spleens and
PDLNs were restimulated overnight with MHC class I- or class II-
restricted viral peptides (2 mg/ml LCMV-GP33, LCMV-NP396,o r
LCMV-GP61) in the presence of Brefeldin A. Cells were stained
for surface expression of CD8 and CD4 and fixed, permeabilized
and stained for intracellular IFNc as previously described [5]. All
antibodies were obtained from BD-Biosciences, Heidelberg,
Germany. Samples were acquired a FACS Canto II flow
cytometer (BD-Biosciences, Heidelberg, Germany).
Determination of Viral Titers by Plaque Assay
Viral titers of organ homogenates were determined by infection
of Vero cells as described [12,15]. Tissues (spleen and pancreas)
were obtained from RIP-LCMV-GP and RIP-LCMV-GP 6
pHHNS-JAM-C (three animals per group) at days 3 and 7 after
infection with 1610
4 LCMV (i.p.). Homogenates and sera were
diluted serially, and viral titers were calculated from the number of
counted plaques.
Statistical Evaluations
Diabetes incidence curves (‘survival curves’) were analyzed
using the Log-rank (Mantel-Cox) test (GraphPad Prism 5.02
Software). Contingency of islet infiltration/insulitis score was
analyzed by the chi-square test and T-cell frequencies were
analyzed using the non-parametric, unpaired, two-tailed Mann-
Whitney test.
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probed for JAM-C expression, insulin production and CD8
+ T cell infiltrations at different times after LCMV-infection.
doi:10.1371/journal.pone.0054675.g001
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LCMV-infection Results in an Upregulation of JAM-C
Around the Islets of Langerhans
To assess the kinetics of JAM-C expression pancreata from RIP-
LCMV-GP mice were harvested at day 0, 4, 7, 10, 14, and 28 after
i.p. infection with 10
4 pfu LCMV and analyzed by immunohis-
tochemistry or immunofluorescence staining. JAM-C was upre-
gulated around the islets predominantly at days 10 and 14 after
LCMV-infection (Figure 1, left panel and Figure 2A). Interesting-
ly, cellular islet infiltration was most pronounced at the time of
strongest JAM-C expression (Figure 1 and Figure 2A, right panel).
At day 10 to 14 post-infection most islets of LCMV-infected RIP-
LCMV-GP mice showed massive peri- and intra-islet CD8
+ T cell
infiltrations (Figure 1, right panel and Figure 2A, right panel). The
presence of high numbers of T cells in and around the islets
resulted in the destruction of islet cells and impaired b-cell function
that finally led to overt disease (Figure 1, middle panel). For
immunofluorescence stainings the constitutively expressed adhe-
sion molecule, CD31, was used as an endothelial cell marker and
Figure 2. Expression of JAM-C after LCMV-infection. – (A) Pancreas sections of RIP-LCMV-GP mice were analyzed for expression of CD31 (red)
and JAM-C (green) as well as CD8
+ T cell infiltrations (red) and JAM-C (green) at different times after LCMV-infection. (B) JAM-C expression (green)
predominantly co-localized with the endothelial cell marker CD31 (red) as shown in higher magnification in a representative pancreas section from
a RIP-LCMV-GP mouse at day 10 post-infection. (C) Evaluation of fluorescence intensity of JAM-C expression at different times after LCMV-infection.
Bars representing mean of 3–8 islets each time point and statistical significance of the fluorescence intensity relative to day 0 were determined using
the unpaired t test (*, p,0.05; **, p,0.005; ***, p,0.0005).
doi:10.1371/journal.pone.0054675.g002
Figure 3. Neutralization of JAM-C reduces the development of T1D. - RIP-LCMV-GP (A) and RIP-LCMV-NP (B) mice were infected with LCMV.
Mice were treated thrice weekly with 100 mg of anti-JAM-C mAb (H33) (filled circles) or isotype-matched control antibody (open circles). Blood
glucose was measured at weekly intervals. For the determination of the incidence mice with values .300 mg/dl were considered diabetic (left
panels). Blood glucose data of all mice are displayed as mean 6 SEM of 13–18 mice per group (right panels). In addition, the mean blood glucose
levels of diabetic RIP-LCMV-NP mice showing a reversion to a non-diabetic state after treatment with anti-JAM-C mAb (reverants) are presented
separately (filled diamonds).
doi:10.1371/journal.pone.0054675.g003
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confocal microscopy (Figure 2B). JAM-C staining co-localized with
CD31 on endothelial cells from pancreatic blood vessels (Figure 2A
and B). As seen previously (Figure 1) a significant increase in
fluorescence intensity of JAM-C expression was detected at day 10
to 14 after LCMV-infection (Figure 2C). Quantification of the
mean intensity of the individual fluorescence channels revealed the
highest JAM-C expression at days 10 and 14 post-infection
(Figure 2C). In comparison to the pancreas of uninfected RIP-
LCMV-GP mice, the expression of JAM-C was increased
significantly (p,0.05) at days 2, 7, peaked at day 10 (p=0.0001)
and day 14 (p=0.015), and declined again at day 21 and 28 after
LCMV-infection (Figure 2C). The quantification of the immuno-
fluorescence staining confirmed the observation that JAM-C
expression parallels the peak of CD8 T cell infiltration (Figure 1
and 2A).
JAM-C Blockade: Neutralization of JAM-C Results in
a Decreased T1D Incidence
In order to investigate if JAM-C might also play a role in the
actual destruction of b-cells and the immunopathogenesis of T1D,
we blocked JAM-C with a neutralizing anti-JAM-C antibody that
disrupts murine JAM-B/2C interactions [16]. In RIP-LCMV-GP
mice anti-JAM-C antibody (100 mg each injection) was adminis-
tered i.p. one day before 10
4 pfu LCMV-infection and then at
days 1, 2, 5, 8, 11, and 14 post-infection. Anti-JAM-C antibody-
treated as well as control RIP-LCMV-GP mice displayed a similar
initial diabetes incidence of approximately 80% within the first 21
days after LCMV-infection (Figure 3A). Interestingly, neutraliza-
tion of JAM-C led to a reversion of T1D two months after LCMV-
infection in that only 47% of the anti-JAM-C antibody-treated
mice remained diabetic compared to 77% of diabetic control
animals. Reverting mice remained non-diabetic throughout the
whole observation period (Figure 3A). In RIP-LCMV-NP mice
anti-JAM-C antibody (100 mg each injection) was administered i.p.
one day before 1610
4 pfu LCMV-infection and then at days 1, 3,
7, post-infection followed by injections twice weekly until day 34
post-infection. In the RIP-LCMV-NP mice the incidence of
diabetes in JAM-C antibody-treated mice was slightly delayed and
reduced to 61% compared to an incidence of 76% in control mice
(Figure 3B). However, this reduction was not significant as
revealed by a log rank (Mantel-Cox) analysis of the survival
curves. The observed minor reduction in T1D severity in RIP-
LCMV-GP and RIP-LCMV-NP mice was only marginally
reflected in the mean blood glucose values. Treatment with anti-
JAM-C antibody resulted in a non-significant decrease of mean
blood glucose levels in RIP-LCMV-NP mice (Figure 3B, right
panel). In contrast, the observed reversion of T1D in some RIP-
LCMV-GP mice was not obvious when analyzing the mean blood
glucose levels of all mice (Figure 3A, right panel). However, the
mean blood glucose decreased markedly when considering the
revertant mice only (Figure 3A, right panel). The rather high
variation (SEM) in blood glucose values results from the different
T1D onset in individual mice of the same group, with some
diabetic mice with blood glucose levels of up to 600 mg/dl and
some still non-diabetic mice with levels below 200 mg/dl.
JAM-C blockade had no effect on viral clearance of LCMV,
since similar viral titers have been found in the pancreas and the
spleen at days 3, 7 and 14 after infection (data not shown). We
then compared islet infiltration in RIP-LCMV-NP mice treated
Figure 4. Neutralization of JAM-C has no influence on insulitis. – (A) Pancreas sections of RIP-LCMV-NP mice were stained for CD8 T cells at
months 6 after LCMV-infection (study end point). (B) Insulitis score was determined in pancreas sections of 8–9 RIP-LCMV-NP mice per group (n=140,
islets analyzed). Scoring system: 0, no infiltration; 1, some peri-insular infiltration; 2, heavy peri-insular infiltration with some intra-insular infiltrates; 3,
heavy intra-insular infiltration and/or islet scars. Representative sections for score 1 to 3 are displayed for control and anti-JAM-C antibody treated
mice (A).
doi:10.1371/journal.pone.0054675.g004
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point of the study at six months after LCMV-infection (Figure 4).
For semi-quantitative assessment of the islet infiltration, an
infiltration score was applied and statistical evaluation was
performed after blinded analysis of the tissue sections. No
significant difference in islet infiltration was found in anti-JAM-
C antibody-treated mice compared to control animals
(Figure 4A+B). Nevertheless, the blocking studies in RIP-LCMV
mice suggest that JAM-C plays a certain role in the pathogenesis of
T1D, since neutralization of JAM-C resulted in a reversion of T1D
in some diabetic RIP-LCMV-GP mice (fast-onset model) and
a reduction of mean blood glucose levels and overall T1D
incidence RIP-LCMV-NP mice (slow-onset model).
Figure 5. Neutralization of JAM-C has no significant influence on the frequency of LCMV-specific T cells. - The presence of LCMV-
specific CD8 T cells on day 7 (A) and 28 (B) after LCMV-infection in the spleen and PDLN of RIP-LCMV-NP mice treated with anti-JAM-C antibody or
isotype-matched control antibody was analyzed by ICCS (IFN-c) after o/n in vitro stimulation with LCMV-GP33 or LCMV-NP396 peptide. Data are the
mean 6 SD of 3–4 mice per group. As internal controls unstimulated cells as well as lymphocytes from a wildtype C57BL/6 mouse (wt) were used.
doi:10.1371/journal.pone.0054675.g005
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is not Significantly Reduced After Neutralization of JAM-C
We next assessed the functional activity of LCMV-specific T
cells after JAM-C blockade in RIP-LCMV-NP mice. Anti-JAM-C
antibody or an isotype-matched control antibody (100 mg each
injection) was administered i.p. one day before 1610
4 pfu LCMV-
infection and then at days 1, 3, 7, post-infection followed by
injections twice weekly until day 26 post-infection. At days 7 and
28 post-infection lymphocytes were isolated from the spleen and
the PDLN and were stained for CD8 and IFN-c after overnight
stimulation with the immunodominant LCMV-peptides NP396
and GP33. At day 7 post-infection a tendency towards a reduction
of GP33-specific CD8 T cells was observed in the spleen and
particularly in the PDLN of anti-JAM-C antibody-treated mice
compared to control animals (Figure 5A). In contrast, during the
autoimmune phase at day 28 post-infection the frequency of GP33-
specific CD8 T cells was similar in JAM-C blocked and control
mice (Figure 5B). More important for the evaluation of the
autodestructive process in RIP-LCMV-NP mice is the frequency
of NP396-specific CD8 T cells. However, both at days 7 and 28 the
frequency of such diabetogenic CD8 T cells was similar in the
spleen and the PDLN of mice that have been treated with the anti-
JAM-C antibody and isotype-matched control antibody (Figure 5).
The results indicate that blockade of JAM-C might have a minor
effect on the initial expansion of LCMV-specific CD8 T cells after
LCMV-infection, but does not influence the frequency of islet-
antigen (LCMV-NP)-specific CD8 T cells during the autoimmune
process b-cell destruction.
Virus-induced Diabetes is not Accelerated in Mice
Expressing Transgenic JAM-C on Pancreatic Endothelial
Cells
In order to further investigate a possible influence of JAM-C on
the immunopathogenesis of T1D, we infected pHHNS-JAM-C
mice that express JAM-C under control of the tie2-promotor
specifically on endothelial cells [13]. Pancreas sections from
pHHNS-JAM-C transgenic and wildtype mice were analyzed for
expression of JAM-C on endothelial cells by immunofluorescence
co-staining with the endothelial cell marker CD31. In comparison
to wildtype C57Bl/6 mice, pHHNS-JAM-C mice express in-
creased levels of JAM-C on pancreatic blood vessels throughout
the entire pancreas section (Figure 6).
We crossed pHHNS-JAM-C mice to RIP-LCMV-GP and RIP-
LCMV-NP mice to evaluate if JAM-C overexpression might result
in an acceleration of T1D. Similar to single transgenic RIP-
LCMV-GP littermates, double transgenic RIP-LCMV-GP 6
pHHNS-JAM-C mice developed T1D in a highly synchronized
fashion between days 12 to 15 (Figure 7A). We found a gender
difference in the T1D incidence in LCMV-infected RIP-LCMV-
NP 6 pHHNS-JAM-C mice (Figure 7B and 7C). Whereas male
RIP-LCMV-NP and RIP-LCMV-NP 6 pHHNS-JAM-C mice
followed a similar pattern of blood glucose elevation as RIP-
LCMV-GP mice (Figure 7B), female RIP-LCMV-NP and RIP-
LCMV-NP6pHHNS-JAM-C mice developed T1D within 2 to 5
months post-infection (Figure 7C). However, both the kinetics and
overall incidence of T1D was similar in RIP-LCMV-NP and RIP-
LCMV-NP6pHHNS-JAM-C mice (Figure 7C). In summary, we
observed that overexpression of JAM-C on endothelial cells did
not have any effect on LCMV-induced T1D neither in the fast-
onset RIP-LCMV-GP line nor in the slow-onset RIP-LCMV-NP
line.
Viral Clearance, Islet Infiltration, and Frequency of LCMV-
specific T Cells are not Changed in RIP-LCMV Mice
Expressing Transgenic JAM-C on Pancreatic Endothelial
Cells
In order to confirm that increased JAM-C expression has only
a minor effect on the immunopathology of virus-induced diabetes
we first assessed the cellular infiltration into the islets of
Langerhans in RIP-LCMV-GP 6 pHHNS-JAM-C mice. RIP-
Figure 6. Characterization of JAM-C expression in the pancreas of pHHNS-JAM-C transgenic mice. - Immmunofluorescence staining of
pancreas sections of pHHNS-JAM-C transgenic and wildtype C57BL/6 mice for JAM-C and the endotheial cell marker CD31. Note that the expression
of transgenic JAM-C co-localizes with CD31 expressing endothelial cells.
doi:10.1371/journal.pone.0054675.g006
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infected with 1610
4 pfu LCMV and the pancreata were removed
at day 6 post-infection. We have chosen such an early time in
order to evaluate a possible acceleration of islet infiltration in
JAM-C overexpressing mice compared to regular RIP-LCMV-GP
mice. However, we were not able to detect a significant increase in
insulitis at day 6 post-infection (Figure 8A). At days 10 and 14
post-infection the islets of RIP-LCMV-GP and RIP-LCMV-GP6
pHHNS-JAM-C mice were already fully infiltrated (data not
shown).
Second, spleens and pancreata from RIP-LCMV-GP 6
pHHNS-JAM-C and RIP-LCMV-GP mice were harvested at
day 3, 7, and 14 after infection with 1610
4 pfu LCMV to analyze
the influence of JAM-C overexpression on viral clearance. In
Figure 7. JAM-C overexpression does not influence the outcome of T1D. - Mean blood glucose levels (left panels) and diabetes incidence
(right panels) of single transgenic RIP-LCMV and double transgenic RIP-LCMV6pHHNS–JAM-C mice that were infected with a single dose of LCMV.
Blood glucose was measured at weekly intervals (values .300 mg/dl were considered diabetic). Data are the mean 6 SEM of 9–26 mice per group.
(A) RIP-LCMV-GP 6pHHNS–JAM-C transgenic mice. (B) Male RIP-LCMV-NP 6pHHNS–JAM-C transgenic mice. (C) Female RIP-LCMV-NP 6pHHNS–
JAM-C transgenic mice.
doi:10.1371/journal.pone.0054675.g007
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PLOS ONE | www.plosone.org 9 January 2013 | Volume 8 | Issue 1 | e54675Figure 8. Increased JAM-C expression has no influence on islet infiltration, viral clearance or antigen specific immune response. - (A)
Pancreas sections of RIP-LCMV-GP 6 pHHNS–JAM-C transgenic mice were stained with Ha ¨matoxylin and the insulitis score was obtained from
sections of 3 mice per group (number of islets analyzed per group are indicated). Scoring system: 0, no infiltration; 1, some peri-insular infiltration; 2,
heavy peri-insular infiltration with some intra-insular infiltrates; 3, heavy intra-insular infiltration and/or islet scars. (B) Virus titers in the pancreas (P)
and spleen (SP) on days 3, 7 and 14 after infection. Data are the mean 6 SD of 3–4 mice per group. Det limit: Minimal number of plaques at highest
tissue homogenate concentration required for statistical evaluation. (C) The presence of GP33-specific CD8
+ T cells on day 10 after LCMV-infection in
the spleen and PDLN of RIP-LCMV-GP or RIP-LCMV-GP6pHHNS-JAM-C mice was analyzed by intracellular cytokine staining (IFN-c) after o/n in vitro
stimulation with GP33 peptide. Data are the mean 6 SD of six mice per group.
doi:10.1371/journal.pone.0054675.g008
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pancreas and the spleen at day 3 post-infection, whereas by day 14
after LCMV-infection no virus was detected in all organs analyzed
(Figure 8B). Importantly, no significant differences in clearance of
LCMV in pancreas and spleen of RIP-LCMV-GP 6 pHHNS-
JAM-C and RIP-LCMV-GP mice was found on days 3, 7 and 14
post LCMV-infection (Figure 8B).
Third, no significant difference in the frequency of LCMV-
specific CD8 T cells in the spleen or the PDLN of RIP-LCMV-GP
6 pHHNS-JAM-C and RIP-LCMV-GP mice was found at day
10 after LCMV-infection (Figure 8C). In both groups of mice the
frequency of IFN-c producing CD8 T cells was approximately 2%
in the PDLN and approximately 10% in the spleen upon ex vivo
stimulation with the immunodominant LCMV peptide GP33
(Figure 8C). Thus, endothelial cell overexpression of JAM-C seems
to have no influence on the viral clearance, the expansion of b-cell-
specific T cells, and the cellular infiltration of the islets in the RIP-
LCMV model. Subsequently, no difference in T1D incidence and
onset was observed.
Discussion
It has been shown that blockade of JAM-C, which plays an
important role in the transmigration of leukocytes through the
endothelial cell layer, reduces cellular infiltration and acinar cell
necrosis in cerulein-induced pancreatitis [9]. The goal of the
present study was to assess the role of JAM-C during the
infiltration of the islets of Langerhans by autoaggressive T cells as
occurring during T1D in a virus-induced mouse model. We found
that JAM-C expression is upregulated around the islets of
Langerhans after infection with LCMV. In particular the highest
JAM-C expression was found at the time when most lymphocytes
are infiltrating the islets. Indeed, upon blockade of JAM-C with
a neutralizing anti-JAM-C antibody we detected a tendency for
a reduced T1D incidence in RIP-LCMV-NP and a reversion of
some diabetic RIP-LCMV-GP mice. However, we were not able
to find significant differences in the degree of cellular infiltration
and the frequency of LCMV-specific T cells.
The RIP-LCMV model comes in two flavors, fast onset (RIP-
LCMV-GP) and slow onset (RIP-LCMV-NP). Because LCMV-
NP is also expressed in the thymus high affinity LCMV-NP-
specific T cells are deleted by central tolerance mechanisms [12].
Thus, in contrast to RIP-LCMV-GP mice, LCMV-infected RIP-
LCMV-NP mice develop T1D much slower and the autodestruc-
tive process is dependent on the presence of LCMV-NP specific
CD4 T cells [11]. Due its milder manifestation therapy of T1D
was often more successful in the RIP-LCMV-NP than the RIP-
LCMV-GP model [15]. In the present study we observed a mild
effect on the progression of T1D upon neutralization of JAM-C in
the fast-onset RIP-LCMV-GP, but not the slow-onset RIP-
LCMV-NP model. However, we did neither find altered
frequencies of LCMV-specific T cells in the spleen and the PDLN
nor significantly reduced cellular infiltration into the islets of
Langerhans.
The lack of a reduction of insulitis was rather surprising, since
JAM-C expression was upregulated around the islets of Langer-
hans and throughout the pancreas upon LCMV-infection and the
highest JAM-C expression coincided with the burst of cellular
infiltration of the pancreas. It has been previously demonstrated
that blockade of JAM-C with the identical neutralizing mono-
clonal antibody that inhibits both JAM-C homophilic interactions
as well as JAM-C/JAM-B heterophilic interactions [16] reduced
the accumulation of leukocytes at the site of inflammation
[9,17,18]. In contrast, it has also been shown that neutrophils
adhere and transmigrate on cultured HUVECs under flow in
a JAM-C independent manner [19]. However, several experi-
mental models of inflammation in mice suggest a substantial
influence of JAM-C on leukocyte extravasation [13,17,20]. JAM-
C, localized in endothelial-cell tight junctions, was shown to be
predominantly involved controlling polarized transmigration.
Interestingly, blocking of JAM-C did not directly affect monocyte
transendothelial migration under flow, but led to increased
monocyte and neutrophil reverse transmigration and return to
the circulation [21]. This observation raises the possibility that the
disruption of the JAM-B/JAM-C interaction might lead to a shift
in the leukocyte entry/exit equilibrium at endothelial junctions.
Thus, an increase of leukocytes with a reverse-transmigratory
behavior might result in the observed tendency of a reversion of
T1D in some RIP-LCMV-GP mice after JAM-C blockade without
visible differences in overall insulitis. Due to the ongoing
inflammation in the islet leukocytes might remain in close
proximity to the islets and might get trapped in a transmigratory
loop as suggested [22].
In order to visualize such a possible transmigratory loop we
transferred splenocytes of P14 TcR-trangenic mice that exclusively
generate CD8 T cells specific for the immunodominat LCMV
epitope GP33 into RIP-LCMV-GP mice challenged with GP33 and
Poly(I:C). In this model JAM-C blockade did not diminish CD8
+
T cell extravasation in vivo as analyzed by two-photon microscopy
at day 7 to 9 after adoptive transfer of P14 splenocytes (data not
shown). Similar to previous experiments [23,24] visualization of
the interaction of infiltrating cells and b-cells within islets
demonstrated a highly diverse migration behavior of individual
cells. However, no difference between anti-JAM-C antibody-
treated and control animals could be observed.
JAM-C overexpression on mouse endothelial cells has been
shown to increase the early influx of inflammatory cells into lungs
after intraperitoneal LPS challenge [13] and upregulate leukocyte
infiltrate and tissue damage in cerulein-induced pancreatitis [9]. In
contrast, in our mouse model for T1D JAM-C overexpression had
no influence on the development of disease. Early infiltration, viral
clearance as well as presence of antigen-specific T cells were
similar in double transgenic JAM-C 6RIP-LCMV and in single
transgenic RIP-LCMV mice. The observed gender difference in
the T1D incidence in LCMV-infected RIP-LCMV-NP 6
pHHNS-JAM-C mice was similar to earlier observations made
in the single transgenic RIP-LCMV-NP mouse line. It has become
evident in the last 5–10 years that young (6–24 wks of age) male
RIP-LCMV-NP mice display an accelerated development of T1D
compared to earlier observations [10,12]. In contrast, male RIP-
LCMV-NP mice older than 24 wks of age rarely develop T1D
after LCMV-infection (Christen & von Herrath, unpublished
observations). No changes to earlier observations have been
detected for female RIP-LCMV-NP mice that still display a slow
onset T1D starting between 1 to 6 months post-infection.
One reason for the contrary findings in the RIP-LCMV and the
cerulein model might be the nature of the different disease model
used. In the cerulein-induced pancreatitic model an inflammation
within the acinar part of the pancreas was induced by the
administration of the chemical compound cerulein that finally
resulted in pancreatitis. This seems to depend mainly on the
infiltration of neutrophils and monocytes rather than lymphocytes.
Hence, the cerulein model is rather different than the virus-
induced RIP-LCMV model and its immunopathogenic processes
involved in the T cell-mediated destruction of b-cells. An
alternative explanation would be that JAM-C overexpression does
not have any influence on virus-induced T1D because unlike to
antibody treatment JAM-C is overexpressed from the beginning of
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this exceptional condition. Further, we found that in contrast to
cerulein-administration infection with LCMV by itself induces
JAM-C upregulation in the pancreas at the time of peak
lymphocyte infiltration. Therefore, the additional transgenic
overexpression might not have an accelerating effect on the
migration of aggressive, islet-specific T cells into the islets.
However, other inflammatory factors, such as the chemokine
CXCL10, have a dramatic effect on the pathogenesis when
overexpressed in the islets of Langerhans [25]. CXCL10 is
expressed in the islets upon LCMV infection [26] and its
neutralization has been shown to reduce T1D severity in the
RIP-LCMV model [1]. Recent evidence however questions a key
role for CXCL10 in T1D [27,28]. Nevertheless, b-cell-specific
overexpression of CXCL10 resulted in a spontaneous infiltration
of the islets of Langerhans and massively accelerated LCMV-
induced T1D in the slow-onset RIP-LCMV-NP model [25].
Thus, JAM-C might only play a minor role in the cellular
infiltration of the islets of Langerhans by b-cell specific T cells and
subsequently the development of T1D. JAM-C might be more
important a factor in the precipitation of lung-associated disorders,
such as acute pulmonary inflammation. JAM-C expression is
strong in the respiratory tract, which is heavily vascularized and
displays high endothelial cell content [13]. Thus, in the lung JAM-
C plays a more crucial role in the transmigration of leukocytes
through the endothelial cell layer to penetrate the site of
inflammation. There is evidence from several studies that adhesion
molecules other than JAM-C indeed have an impact on the
development of T1D. In an adoptive transfer model of diabetes in
NOD mice the neutralization of L-selectin or very late antigen 4
(VLA-4) that are expressed on migrating leukocytes and interact
with adhesion molecules expressed on the endothelial cells resulted
in a reduction of T1D [29]. Moreover, the treatment with an
antibody neutralizing vascular cell adhesion molecule-1 (VCAM-
1) delayed the onset of disease, whereas blocking antibody against
intercellular adhesion molecule-1 (ICAM-1) had only a marginal
effect on the onset of T1D [30]. ICAM-1 is constitutively
expressed in low concentrations on endothelial cells and is highly
upregulated during inflammation. In contrast, VCAM-1 is only
expressed on endothelial cells after cytokine stimulation, binds to
VLA-4 and mediates adhesion of leukocytes to the endothelium
[31,32]. These data indicate that the interaction of VLA-4/
VCAM-1 seems to be crucial for the rolling and adhesion of
leukocytes to the site of injury in this adoptive transfer model of
diabetes in NOD mice and the CD11b or lymphocyte function
associated antigen 1 (LFA-1) interaction with ICAM-1 has less
impact in this mouse model. Other than VCAM-1 and ICAM-1,
JAM-C seems to play a minor role in rolling and adhesion of
leukocytes and is rather crucial in transmigration of leukocytes
through the endothelial cell layer to enter the site of inflammation
[20]. JAM-C interacts with CD11b and CD11c mediating
extravasation of leukocytes [2,16]. Collectively these data and
our findings in the RIP-LCMV model suggest that JAM-C/
CD11b interaction plays only a minor role in the pathogenesis of
T1D.
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